Drugs / arginine/lysine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04524442 | Jan 2021 → Nov 2023 | digestive system neuroendocrine neoplasm | Advanced Accelerator Applications | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arginine/lysine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04524442 ↗ |
| Route | Intravenous | “administered intravenously over a 4-hour period” NCT04524442 ↗ |